RxDoctor Payments Data

Nathan Pirakitikulr, MD

Ophthalmic Plastic and Reconstructive Surgery · Solana Beach, CANPI 1700316817

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Amgen at 38.9% of the total. Reporting peaked in 2024 at $1,395 and has fallen 50.7% since, to $688 in 2025.

$3,845in general payments, 2019–2025

Across 48 payments — averaging $80.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$673
  • Sight Sciences, Inc.$456
  • Alcon$250
  • Glaukos Corporation$217
  • Argenx US, Inc.$150
  • plus $601 from 6 others

What the payments were for

  • Food & beverage$3,845100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,845 in reported general payments places this provider in the 65th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.

See all ophthalmic plastic and reconstructive surgery providers in California

Medicare billing

Part B allowed, 2024
$75,421
Medicare patients
139
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base26$201

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Solana Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →